Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer

BACKGROUND: The treatment of endometrial cancer (EC), the most common gynecological cancer, is currently hampered by the toxicity of current cytotoxic agents, meaning novel therapeutic approaches are urgently required. METHODS: A cohort of 161 patients was evaluated for the expression of the recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Healey, Gareth D., Pan-Castillo, Belen, Garcia-Parra, Jezabel, Davies, Julia, Roberts, Shaun, Jones, Eilir, Dhar, Kalyan, Nandanan, Sarika, Tofazzal, Nasima, Piggott, Luke, Clarkson, Richard, Seaton, Gillian, Frostell, Asa, Fagge, Tim, McKee, Colin, Margarit, Lavinia, Conlan, R. Steven, Gonzalez, Deyarina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820928/
https://www.ncbi.nlm.nih.gov/pubmed/31665084
http://dx.doi.org/10.1186/s40425-019-0765-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820928/
https://www.ncbi.nlm.nih.gov/pubmed/31665084
http://dx.doi.org/10.1186/s40425-019-0765-z

Ejemplares similares